BioMarin Pharmaceutical Inc. (BMRN) key performance indicators and operating metrics (14 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Non-GAAP Operating Margin | 24.30 percent | FY2026-Q1 |
| Operating Margin (GAAP) | 16.90 percent | FY2026-Q1 |
| ALDURAZYME Net Product Revenues | 37M | FY2026-Q1 |
| BRINEURA Net Product Revenues | 47M | FY2026-Q1 |
| KUVAN Net Product Revenues | 24M | FY2026-Q1 |
| NAGLAZYME Net Product Revenues | 130M | FY2026-Q1 |
| PALYNZIQ Net Product Revenues | 90M | FY2026-Q1 |
| ROCTAVIAN Net Product Revenues | 3M | FY2026-Q1 |
| VIMIZIM Net Product Revenues | 210M | FY2026-Q1 |
| Non-GAAP Income | 149M | FY2026-Q1 |
| Research and Development Expense (Non-GAAP) | 167M | FY2026-Q1 |
| Selling, General and Administrative Expense (Non-GAAP) | 222M | FY2026-Q1 |
| Number of Countries Treating Patients With VOXZOGO for Achondroplasia | 55.00 | FY2025-Q3 |
| Weighted-Average Diluted Shares Outstanding (Non-GAAP) | 196.5M | FY2025-Q1 |
Back to BMRN overview · BMRN earnings · BMRN holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.